Dianthus Therapeutics, Inc. DNTH
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +99.90%
- 1 year
- +144.16%
- Open
- 81.29
- Prev close
- 82.70
- Mkt cap
- 4.61B
- Vol
- 496.89K
- Avg vol
- 822.37K
- EPS
- -4.24
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 80.63
- High
- 83.73
- Forward P/E
- -17.87
- Beta
- 0.18
- Short ratio
- 9.16
- Inst. own
- 128.66%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 93.30
- 200-d avg
- 84.85
- 1y target
- 139.06
5D chart
Events in this range
- Oct 27, 2026Rating: Roth Capital · — → Buy
Signals (114)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:10 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:00 AM | 2 days ago |
| RSI: Overbought | Oct 28, 3:45 PM | 3 days ago |
| RSI: Overbought | Oct 28, 3:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| RSI: Overbought | Oct 28, 2:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:25 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:45 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:20 AM | 5 days ago |
News
4 days ago benzinga.com
This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts initiated Buy coverage on DRIO ($6), WATT ($15), PPL ($41), DNTH ($113); PYPD rated Outperform with a $10 target.
-
4 days ago benzinga.com
Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113
Roth Capital analyst Adam Walsh initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $113.
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $158 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and maintains $158 price target.
2 weeks ago globenewswire.com
Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma
NEW YORK and WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
3 weeks ago benzinga.com
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
Oversold health care stocks Align Technology, Dianthus Therapeutics and Ocular Therapeutix show RSI readings near or below 30, signaling potential value.
1 month ago globenewswire.com
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
1 month ago globenewswire.com
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
1 month ago benzinga.com
This Shopify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Wall Street analysts initiated coverage on PPG, Shopify, Chesapeake Utilities, Global Payments and Dianthus, with targets ranging from $101 to $160.
-
1 month ago benzinga.com
JP Morgan Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135
JP Morgan analyst Brian Cheng initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Overweight rating and announces Price Target of $135.
1 month ago seekingalpha.com
Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
-
1 month ago benzinga.com
Citigroup Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $156
Citigroup analyst Samantha Semenkow initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $156.
1 month ago globenewswire.com
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
2 months ago globenewswire.com
Dianthus Therapeutics to Participate in Three Investor Conferences During September
NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
2 months ago defenseworld.net
Alyeska Investment Group L.P. Has $14.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
Alyeska Investment Group L.P. increased its position in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 188.2% in the undefined quarter, according to the company in its most recent filing…
2 months ago seekingalpha.com
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case
Dianthus Therapeutics is building a neuromuscular franchise around claseprubart, differentiated by clinical profile and financial independence. DNTH holds ~$1.2B in cash and investments, supporting…
2 months ago globenewswire.com
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today…
2 months ago defenseworld.net
California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH
California State Teachers Retirement System boosted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 155.5% in the undefined quarter, according to the company in its most recent…
2 months ago defenseworld.net
Dimensional Fund Advisors LP Purchases 114,767 Shares of Dianthus Therapeutics, Inc. $DNTH
Dimensional Fund Advisors LP lifted its position in Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 54.5% in the first quarter, according to its most recent filing with the Securities and Exchange…
2 months ago zacks.com
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to a loss of $0.88 per share a year ago.
2 months ago globenewswire.com
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic…
2 months ago globenewswire.com
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms…
2 months ago globenewswire.com
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
4 months ago globenewswire.com
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
4 months ago globenewswire.com
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28
4 months ago zacks.com
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.
4 months ago benzinga.com
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported stronger-than-expected midstage results from its CAPTIVATE Phase 3 trial of claseprubart (DNTH103) in chronic inflammatory demyelinating…
4 months ago benzinga.com
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says
Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst reaction.
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
4 months ago seekingalpha.com
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
7 months ago benzinga.com
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy rating, $88 PT. See analyst ratings.
7 months ago benzinga.com
AutoZone To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts change outlook on top names: Truist cut KFY price target, Oppenheimer raised AZO target, B. Riley slashed YEXT target, Stifel cut MTN target, RBC raised KNTK target, Truist cut MAA target,…
7 months ago benzinga.com
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Wall Street analysts upgraded CRWD, ALEC, RIVN, SEDG, and DNTH. See what other analysts say about these stocks. Consider buying CRWD.
7 months ago benzinga.com
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
8 months ago benzinga.com
Latham Group, Babcock & Wilcox, B&G Foods And Other Big Stocks Moving Higher On Wednesday
Dow falls 100 pts, Latham Group Inc (SWIM) rises 25.7%, Babcock & Wilcox Enterprises Inc (BW) gains 23%, B&G Foods Inc (BGS) rises 20.4%.
11 months ago benzinga.com
The Insider Report: Prepare for the Next Dip Buying Opportunity
The Insider Report: Prepare for the Next Dip Buying Opportunity
1 year ago benzinga.com
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
-
2 years ago benzinga.com
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.